Securities code: Asymchem Laboratories (Tianjin) Co.Ltd(002821) securities abbreviation: Asymchem Laboratories (Tianjin) Co.Ltd(002821) Announcement No.: 2022024 Asymchem Laboratories (Tianjin) Co.Ltd(002821) Pharmaceutical Group (Tianjin) Co., Ltd
Announcement of main business data from January to February 2022
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and there are no false records, misleading statements or major omissions.
1、 Main operating data from January to February 2022
Since this year, the company has maintained a strong growth momentum. While continuing to undertake large orders, the business of other sectors has shown a momentum of accelerated growth. From January to February, the scale of orders on hand and the growth of revenue reached a record high. According to the preliminary accounting of the company, the operating revenue from January to February increased by more than 130% year-on-year. The company expects that the operating revenue in the first quarter of 2022 will increase by more than 150% year-on-year, with an amount of more than 2 billion yuan.
2、 Explanatory matters
1. The above main operating conditions are the preliminary accounting results of the company’s financial department, which are only used as phased instructions for investors’ reference. They have not been audited and cannot be used to calculate the company’s annual performance.
2. China Securities Journal, securities times and cninfo (www.cn. Info. Com. CN.) For the information disclosure newspapers and websites designated by the company, the information published by the company shall be subject to the announcement published in the above designated newspapers and websites. Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Asymchem Laboratories (Tianjin) Co.Ltd(002821) Pharmaceutical Group (Tianjin) Co., Ltd. board of directors March 14, 2002
